ArticleCureus2026
When Rapid Response Becomes Catastrophic: Tumor Lysis Syndrome Following Cisplatin-Etoposide Therapy in Extensive-Stage Small Cell Lung Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS) is an oncologic emergency characterized by severe metabolic derangements resulting from rapid tumor cell breakdown. We present the case of a 66-year-old man with extensive-stage small cell lung cancer (SCLC) involving the mediastinum, pleura, and left upper lobe, who developed TLS shortly after initiation of cisplatin-etoposide chemotherapy. Laboratory evaluation demonstrated hyperuricemia, hyperkalemia, hyperphosphatemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH)-related hyponatremia, and acute kidney injury, consistent with TLS. Imaging revealed extensive intrathoracic disease with a large left pleural effusion and mediastinal involvement. The patient required aggressive electrolyte management and close monitoring following chemotherapy initiation. This case emphasizes the importance of maintaining clinical suspicion for TLS in patients with bulky SCLC receiving cytotoxic therapy and highlights the need for early recognition and prompt intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.